Company* |
University/ Nonprofit@ |
Type Of Agreement |
Product Area |
Details (Date) |
Acacia Research |
The Centre for Applied Genomics (Canada) |
Partnership |
To gain access to the consortium's published markers for autism |
Acacia's division CombiMatrix Molecular Diagnostics plans to use them in upcoming versions of its Constitutional Genetic Array Test (3/7) |
Advanced Cell |
Casey Eye Institute at Oregon Health and Science University |
Sponsored research agreement |
To conduct preclinical studies for its retinal pigment epithelium program |
The research team is conducting a dosage study using the company's RPE cells in a rat model and plans to conduct similar studies in other rodent models of retinal degenerativedisease (2/6) |
Affymetrix |
Baylor College of Medicine |
License agreement |
Baylor got rights to Affymetrix patents covering comparative genomic hybridization microarray services |
The nonexclusive license covers services in Clinical Laboratory Improvement Amendments environments; terms of the deal were not disclosed (12/5) |
Affymetrix |
Vanderbilt- Ingram Cancer Center |
Translational research collaboration |
Three-year agreement to analyze genomic information across a large number of patient samples |
Researchers will use Affymetrix GeneChip microarray technol- ogy to develop new applications for translational research (1/24) |
Aruna |
University of Georgia Research Foundation |
License agreement |
Agreement to develop and commercialize neural cells derived from human embryonic stem cells |
Aruna will offer researchers access to human neural cells that relate to normal and diseased conditions (1/26) |
Asuragen Inc.* |
Yale University |
License agreement |
For exclusive access to rights in inventions developed by Frank Slack for the regulation of oncogenes by microRNAs |
A collaboration revealed that human let-7 regulates the expression of ras and that misregulation of let-7 in human lung cells likely contributes to the development of lung cancer via altered expression of ras (1/10) |
AVAX |
Cancer Treatment Centers of America |
Agreement |
Focused on AVAX's O-Vax therapeutic for ovarian cancer and CTCA's activated natural killer cell technology for various human cancers |
AVAX will receive more than $1M in research and development funding (2/21) |
Avicena |
National Institute of Neurological Disorders and Stroke |
Agreement |
Avicena will supply PD-02 for a Phase III trial that is being planned by NINDS |
PD-02 is a neuroprotective agent Avicena is developing for Parkin- son's disease; it gets rights to use the study's findings (12/6) |
Bio-Bridge |
Chinese Academy of Medical Sciences |
Cooperative agreement |
To develop a human papillomavirus vaccine expected to provide broader protection than Gardasil with lower production costs |
Bio-Bridge has assumed 60% interest in the project and will receive preferential rights to develop the vaccine (3/9) |
BioCurex |
Blokhin Cancer Research Center (Russia) |
Collaboration |
Deal to further develop and evaluate BioCurex's RECAF technology |
The RECAF marker will be tested in cancer screening, diagnosis and follow-up of treated patients (12/7) |
BioE Inc.* |
University of Texas M.D. Anderson Cancer Center |
Research partnership |
To evaluate the potential of BioE's cord blood stem cell, the Multi-Lineage Progenitor Cell, to help treat cancer |
Researchers will study the technology's utility as an antitumor protein delivery vehicle (1/29) |
BioNanomatrix |
Radiation Biology Branch at the National Cancer Institute |
CRADA |
Agreement to use BioNanomatrix's whole-genome analyzer to develop methods to detect, identify and quantify DNA damage caused by ionizing radiation |
The initial focus is on assessing radiation-induced damage to DNA (1/18) |
BioServe |
Harvard University and the University of Michigan |
Agreement |
BioServe will perform DNA purification and genotyping on tissue samples collected from 750 school children in Chennai, India, who have been exposed to lead pollutants |
The effort is part of a study by the universities on how genetics and environmental lead pollution interact to affect children's intellectual and behavioral functioning (1/24) |
Biotage AB |
McMaster University |
Agreement |
To develop a new chemistry platform to speed the production of molecular imaging and therapy agents |
Biotage will provide funding and instruments (2/26) |
BioTrove Inc.* |
Stanford University Genome Technology Center |
License |
Stanford will use the BioTrove OpenArray technology platform to advance its multiple research projects |
Applications are expected in single nucleotide polymorphism genotyping, real-time quantitative polymerase chain reaction-based tests, and the development of novel uses for the Open-Array system(2/27) |
Cepheid Inc. |
Idaho Technology Inc. |
Settlement and cross- license agreement |
To resolve a dispute related to the intellectual property in rapid polymerase chain reaction methods and instrumentation, the use of SYBR Green I in PCR reactions and certain methods of analysis of real-time PCR data |
The settlement resolves all claims from a lawsuit started in 2005 by Idaho Technology and its licensor, University of Utah Research Foundation; Cepheid made a one- time payment to Idaho of $3.35 million (1/11) |
Champions |
Johns Hopkins University |
Patent rights agreement |
For patents encompassing two benzoylpheny-lura sulfura analogue compounds that have shown activity against prostate and pancreatic cancer cell lines |
The antimitotic inhibitors target microtubule-associated protein tau-deficient tumors; rights were exchange for 550,000 restricted shares of common stock (2/14) |
Cleveland |
Roswell Park Cancer Institute |
Partnership |
To develop the company's cancer and radioprotectant drug candidates |
Roswell Park and other New York agencies will provide the company with up to $5 million and Cleveland BioLabs will establish a research facility at the Roswell Park campus (1/12) |
Copernicus |
Cystic Fibrosis Foundation Therapeutics Inc. |
Agreement |
To support continued development of a gene therapy for cystic fibrosis |
Copernicus will receive up to $5.2M in funding (2/15) |
DiaDexus Inc.* |
Mayo Validation Support Services (affiliate of the Mayo Clinic) |
Collaboration |
To investigate a test featuring a select panel of tumor-specific genes |
The test will aid in patient risk stratification and assist in chemotherapy treatment decisions for breast cancer patients (1/10) |
Dyadic |
Royal Nedalco (the Netherlands) |
Research and development project |
Dyadic joined others in a project sponsored by the Netherlands government to develop technologies of ethanol production from sugar beet pulp and wheat bran |
Dyadic Nederland BV, the company's subsidiary in Zeist, the Netherlands, will focus on the development of optimal enzyme preparation for the extraction of sugars from those feedstocks (1/16) |
Elusys |
U.S. Army Medical Research Institute of Infectious Diseases |
CRADA |
They extended agreement for R&D of therapeutics against anthrax and other biowarfare agents |
The extension focuses on applying Elusys' HP Antibody technology as a platform for developing countermeasure agents (12/13) |
Epiphany |
Columbia University |
Licensing agreement |
For the diagnostic and therapeutic use of the KSHV/HHV-8 sequence and related patents |
Epiphany previously had an exclusive option to the portfolio; KSHV or HHV-8 has been shown to cause serious and life-threat- ening disease such as cancer, especially in immuno compromised and HIV-positive patients (1/10) |
Galapagos NV |
The ALS AssociationTherapeutics Inc. |
Collaboration |
Galapagos will discover drug targets fordevelopment of drugs for amyotrophic lateral sclerosis |
Galapagos may get up to $3M in the deal; it also has an option todevelop certain resulting targets (12/11) |
Galapagos NV |
University of Bristol (UK) |
Agreement |
In the field of cancer research |
Galapagos' service division, BioFocus DPI, will provide leadoptimization services for a university research program focusing on destroying cancer cells; total contract value exceeds €2M (US$2.6M) (2/15) |
Genesis |
Firebird Global Master Fund II Ltd. |
Investment |
The investment comes in the form of a $0.5Mconvertible promissory note |
Under the terms, the company will acquire rights to the Mammastatin therapeutic technology from the University of Michigan,and the company's subsidiary, Prion Developmental Laboratories, will begin production of the mad cow disease rapid assay teststrips (2/9) |
GeneGo Inc.* |
St. Jude Children's Research Hospital |
Licensing agreement |
For the data mining suite, MetaCore |
MetaCore 4.2 includes a new ontology of cellular process networks, as well as additional functional processes and more genes have been networked using GeneGo network algorithms (1/30) |
Genentech Inc. |
Walter and Eliza Hall Institute of Medical Research (Australia) |
Exclusive global collaboration agreement |
To discover, develop, manufacture and commercialize a new class of broad- spectrum cancer therapeutics |
Genentech will make up-front and research program payments, with the possibility of milestone and royalty payments in the future (2/6) |
GenPat77 |
Charite University of Medicine (Germany) |
License agreement |
GenPat got rights to an investigational cancer therapy, GP7.1 |
GP7.1 has been tested in a pilot study in patients with neuroblastoma; terms of the worldwide license were not disclosed (12/7) |
GenVec Inc. |
Department of Homeland Security |
Three-year contract |
To support development and manufacture of adenovector- based vaccines against foot-and- mouth disease |
Company will receive up to $6M in program funding the first year and up to $15M over three years (2/1) |
GenVec Inc. |
Naval Medical Research Center |
Collaboration |
To conduct the first clinical study of a malaria vaccine developed using the company's gene delivery and cell culture manufacturing technologies |
The technologies are used to produce recombinant adeno-virus vaccine vectors (1/17) |
Gilead |
International Partnership for Microbicides and CONRAD |
License agreement |
IPM and CONRAD got certain rights to use of tenofovir as a microbocide |
The nonprofits would be able to distribute the product in about 100 resource-limited countries for preventing HIV (12/11) |
HemoBioTech |
Texas Tech University Health Science Center |
Extended sponsored research agreement |
To focus on commercial development of the company's HemoTech product as a substitute for human red blood cells |
HemoBioTech is paying about $780,000 to extend the agreement (2/1) |
Illumina Inc. |
Children's Hospital of Eastern Ontario |
Research collaboration |
To develop molecular diagnostic tests to screen newborn babies for spinal muscular atrophy and hemoglobinopathies |
Illumina and CHEO initially will develop assays to screen newborns using Illumina's VeraCode technology and BeadXpress reader (1/8) |
Illumina Inc. |
Mayo Clinic |
Collaboration |
To co-develop molecular diagnostic tests for the study of complex diseases |
Illumina will contribute its Vera- Code technology and development expertise for the BeadArray and BeadXpress instrument platforms; it will manufacture and market tests worldwide (1/10) |
Introgen |
University of Texas M.D. Anderson Cancer Center |
License agreement |
Introgen got worldwide rights to use INGN 241 (mda-7/IL-24) with several types of existing therapies |
Introgen is testing INGN 241 in Phase II and III cancer trials; terms of the deal were not disclosed(12/21) |
KeyNeurotek AG* |
Max Planck Innovation GmbH (Germany) |
License agreement |
To cover a method to identify drug candidates at the Enzymology of Protein Folding research unit |
Financial terms were not disclosed (2/15) |
Lipomics |
University of California, Davis |
Agreement |
To collaborate on research projects with an emphasis on personalized medicine |
Lipomics will retain certain rights to develop diagnostic applications based on the data from the studies (2/27) |
MacroGenics Inc.* |
Juvenile Diabetes Research Foundation |
Partnership |
To support a pivotal multinational Phase II/III trial of teplizumab (MGA031) |
The compound has shown promise in slowing the progression of Type I diabetes in children and adults newly diagnosed with the disease (1/3) |
Medistem |
Rio Valley Medical Clinic |
Technology licensing and royalty agreement |
Any product derived from or involving infusion-quality adult stem cells |
Medistem will receive a 90% royalty of the monthly net revenue in excess of $20,000 resulting from the clinic's sale of the products (1/5) |
Mimetic |
University of Texas |
Licensing agreement |
For Affinimer Chemistry |
The technology allows for the creation of chemically engineered smart polymers that can bind specific "trigger" molecules and subsequently release a drug or other agent under preprogrammed conditions (3/7) |
Novavax Inc. |
University of Massachusetts Medical School |
Technology agreement |
Novavax gained worldwide rights to a new virus-like particle technology |
The technology uses paramyxo- viruses as a core for building a VLP vaccine; the agreement covers VLP vaccines for preventing any viral disease in humans (3/2) |
Ovation |
National Institute on Drug Abuse |
CRADA |
Five-year agreement to study the company's anticonvulsant product, vigabatrin, for cocaine and methamphetamine dependence |
Ovation and NIDA will jointly design and implement preclinical studies, as well as clinical trials (1/23) |
PhytoMedical |
Iowa State University |
Sponsored research agreement |
Expanded agreement regarding development of the company's synthesized type A-1 polyphenolic compounds for Type II diabetes |
The agreement allows for the continuation of research under a July 2006 agreement; the compounds are derived from cinnamon (3/7) |
Poniard |
The Scripps Research Institute |
Expanded research agreement |
To include the discovery of focal adhesion kinase inhibitors to treat cancer |
Original agreement was signed in August 2005 and covered the discovery of small-molecule protein kinase inhibitors as therapeutic agents (1/10) |
Presidio |
Stanford University |
Licensing agreement |
To a hepatitis C virus technology |
The technology is designed to target a specific region found in the HCV proteins NS4B and NS5A, viral proteins needed for virus replication (1/16) |
Protein |
University of Arizona |
Materials transfer agreement |
To provide genetically engineered protein polymers to the university |
The university plans to design, fabricate and test the properties of protein-based biomaterials and scaffolds for applications in tissue engineering and regenerative medicine using PPTI's protein polymers (1/29) |
pSivida Ltd. |
Faber Research LLC |
License agreement |
To develop pSivida's Durasert, Zanisert and Co-Drug drug delivery technologies for infectious disease and diseases of the ear |
Faber will make $990,000 in payments to pSivida for the right to exclusively negotiate a licensing agreement for a period of three months and to fund the cost of a preclinical study (1/9) |
ReNeuron Group |
Ludwig Institute of Cancer Research and the Dana-Farber Cancer Institute |
Revenue- sharing agreement |
Concerns recently patented research conducted by the institutions on certain gene-based somatic cell expansion technology |
ReNeuron is entitled to revenues based on a 1998 agreement (2/26) |
Rexahn |
National Institute of Neurological Disorders and Stroke Screening Program |
Agreement |
For the company's lead CNS compound, RX-10100, to be submitted to NINDS' Anticonvulsant |
The program is focused on discovery, optimization and development of drugs for epilepsy and other serious conditions (2/5) |
RXi |
University of Massachusetts Medical School |
Expanded agreement |
Companies signed a master agreement to provide RXi option rights to license all unrestricted therapeutic RNAi technology developed at UMMS over the next three years |
The license would be in return for cash payments and equity; option rights are contingent upon RXi's receipt of working capital funding in the coming months (1/16) |
Sangamo |
City of Hope |
License agreement |
Sangamo got exclusive rights to chimeric immunoreceptor tech- nology, which will be tested against cancers |
They also will work to develop a cell therapy using the technology with Sangamo's zinc-finger tech ology; COH gets an up-front license fee and annual fees, and is eligible to get milestone and royalties payments (12/11) |
Santhera |
Translational Research in Europe- Assessment and Treatment of NeuroMuscular Diseases |
Collaboration |
Santhera joined the TREAT-NMD network, which is coordinating research into rare neuromuscular diseases |
TREAT-NMD is being funded by a five- ear, E10M European Union grant; it includes 21 academic and commercial organizations in 11 European countries(11/29) |
S*BIO Pte. Ltd.* (Singapore) |
Department of Tumorbiology and Microbiology at the Karolinska Institute(Sweden) |
Research collaboration |
To evaluate the role of the company's histone deacetylase inhibitors |
Researchers will evaluate the inhibitors in colorectal cancer and investigate the underlying mechanisms of the development of gastrointestinal polyps and tumors (1/10) |
S*BIO Pte. Ltd.* |
Agency for Science, Technology and Research's Institute of Molecular and Cell Biology(Singapore) |
Research collaboration |
For the discovery and development of multiple oncology compounds |
S*BIO will provide expertise in high- throughput screening, medicinal chemistry and the identification and optimization of lead compounds, while the institute will use its targets and assays to screen for chemical starting points (2/7) |
Sequenom Inc. |
The Chinese University of Hong Kong |
Exclusive rights agreement |
For noninvasive prenatal diagnostic intellectual property |
Sequenom also obtained exclusive rights to a portfolio of methylation and nucleic acid markers; financial terms were not disclosed (2/13) |
SensiGen LLC* |
University of Michigan |
Exclusive license agreement |
For a human papilloma-virus detection test developed at the university |
The technology, called the Atto- Sense HPV Test, has demonstrated the ability to detect as few as one to three copies of HPV DNA in any blood or tissue sample, and also to clearly identify in a single assay each of the 15 unique genotypes of HPV that cause cervical cancer in women (2/22) |
Sirtris |
Massachusetts Institute of Technology |
License agreement |
Sirtris got exclusive rights to develop assay and gene therapy technologies using the SIRT1 gene |
Sirtris will use the technology to further advance its sirtuin platform focused on therapeutics for diseases of aging; terms of the deal were not disclosed (11/30) |
Stemagen* |
University of Pennsylvania |
Exclusive rights agreement |
To a patent that covers a technique for the development of uniparental embryonic stem cells |
Stemagen has created uniparental embryonic stem cell lines, which are derived from the genetic material of an egg or sperm only, rather than a fertilized egg(3/5) |
Stemline |
Duke University, the British Columbia Cancer Agency and the Scott & White Cancer Research Institute |
Exclusive, worldwide licensing agreement |
For SL-401, a compound aimed at a cancer stem cell target |
SL-401 is designed to target the interleukin-3 receptor, and early data demonstrated that it could impair the ability of cancer stem cells to form tumors (3/7) |
Stratagene Corp. |
Max Planck Innovation (Germany) |
Co-exclusive license agreement |
To more than 150 microRNA sequences |
Stratagene will have the right to use the microRNA sequences for the development, manufacture and sale of molecular diagnostic |
Trana |
Southern Research Institute |
Collaboration |
Deal to discover new classes of drugs for treating HIV |
Trana will screen SRI's collection of nucleosides to discover anti-infectives that act through the inhibition of transfer RNA (12/13) |
VASTox plc (UK; |
European Union |
Research project |
VASTox became a partner in the Targeting Cancer Stem Cells for Therapy project |
The company will work with five research organizations to develop treatments that target cancer stem cells; initial research will focus on leukemia and breast cancer (1/17) |
Waypharm SA*(France) |
Cancer Research Technology Ltd. (UK) |
Agreement |
To license Thioplatin, a hypoxia- esponsive platinum-based cancer therapy |
CRT granted Waypharm an exclusive six- month option to worldwide development and commercialization rights and will receive an up-front payment plus licensing fees, and milestone and royalty payments (2/5) |
XDx Inc.* |
University of Minnesota |
Agreement |
To exclusively license technology related to the use of gene expression to assess the disease status of systemic lupus erythematosus patients |
XDx and the university also entered a deal with The FeinStein Institute that provides XDx access to SLE patient samples collected through an NIH-funded program to elucidate biomarkers of autoimmune diseases (2/20) |
Xpention |
University of Texas Health Science Center Immunological Test |
Extended research agreement |
The extension through May 31, 2007, will permit the completion of a project titled "Development of the p65 technology |
It also will permit the continued collaboration with Margaret Hanausek, one of the co-inventors of the p65 technology (2/20) |
Xytis Inc.* |
National Institute of Drug Abuse |
CRADA |
To further evaluate Neboglamine (XY2401) as a treatment for cocaine addiction |
The company will test whether the antipscyhotic compound can help addicts abstain from the narcotic or prevent them from relapsing into addiction (1/8) |
Notes: | ||||
This chart does not include grants or contract awards, or agreements between biotech companies and clinical | ||||
trial centers. | ||||
* Denotes privately held company. | ||||
@ Some institutions listed have for-profit components. They are located in the U.S. unless otherwise noted. | ||||
CRADA = Cooperative Research and Development Agreement. | ||||
Unless otherwise noted, shares are traded on the Nasdaq exchange. | ||||
AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange. | ||||